bristol-myers squibb

KogeLiz

Bristol-Myers Squibb Agrees To Pay $19.5M Over Improper Marketing Of Medication

Prescription medication, when used properly and safely, can provide needed relief to consumers suffering a wide range of illnesses or physical conditions. However, those medications must be marketed and advertised properly. That apparently wasn’t the case for a antipsychotic prescription drug manufactured Bristol-Myers Squibb (BMS). As a result, the company has agreed to pay $19.5 million in a settlement with 42 states and the District of Columbia.  [More]

Drug Company Fined MoreThan $500 Million For Inflating Drug Prices, Inappropriate Marketing

Drug Company Fined MoreThan $500 Million For Inflating Drug Prices, Inappropriate Marketing

Given all the recent attention to industry money and off-label uses of atypical antipsychotics, we were particularly struck by the Abilify issue. The drug is approved only for bipolar disorder and schizophrenia in adults, but the Department of Justice accused the company of promoting its use for children and for elderly patients with dementia.

According to the Department of Justice, BMS created a special sales force specifically to target nursing homes. It’s unfortunate for those patients that the drug carries a warning of increased death among elderly patients with dementia-related psychosis who are treated with atypical antipsychotics.